nodes	percent_of_prediction	percent_of_DWPC	metapath
Amlexanox—FGF1—artery—uterine cancer	0.0317	0.0771	CbGeAlD
Amlexanox—S100A12—myometrium—uterine cancer	0.0245	0.0597	CbGeAlD
Amlexanox—S100A13—epithelium—uterine cancer	0.0195	0.0475	CbGeAlD
Amlexanox—S100A12—epithelium—uterine cancer	0.0193	0.0468	CbGeAlD
Amlexanox—S100A12—uterine cervix—uterine cancer	0.0191	0.0464	CbGeAlD
Amlexanox—S100A13—smooth muscle tissue—uterine cancer	0.0188	0.0457	CbGeAlD
Amlexanox—S100A12—decidua—uterine cancer	0.0182	0.0442	CbGeAlD
Amlexanox—S100A13—renal system—uterine cancer	0.0181	0.044	CbGeAlD
Amlexanox—IL3—lymph node—uterine cancer	0.0179	0.0435	CbGeAlD
Amlexanox—S100A12—mammalian vulva—uterine cancer	0.0167	0.0406	CbGeAlD
Amlexanox—S100A13—female reproductive system—uterine cancer	0.0145	0.0353	CbGeAlD
Amlexanox—S100A13—female gonad—uterine cancer	0.0132	0.0321	CbGeAlD
Amlexanox—S100A12—female gonad—uterine cancer	0.013	0.0317	CbGeAlD
Amlexanox—S100A12—vagina—uterine cancer	0.0129	0.0315	CbGeAlD
Amlexanox—FGF1—epithelium—uterine cancer	0.012	0.0292	CbGeAlD
Amlexanox—FGF1—smooth muscle tissue—uterine cancer	0.0116	0.0282	CbGeAlD
Amlexanox—FGF1—renal system—uterine cancer	0.0112	0.0271	CbGeAlD
Amlexanox—PDE4A—decidua—uterine cancer	0.0107	0.0261	CbGeAlD
Amlexanox—FGF1—female reproductive system—uterine cancer	0.00893	0.0217	CbGeAlD
Amlexanox—PDE4D—female gonad—uterine cancer	0.00869	0.0211	CbGeAlD
Amlexanox—S100A13—lymph node—uterine cancer	0.00849	0.0206	CbGeAlD
Amlexanox—S100A12—lymph node—uterine cancer	0.00837	0.0204	CbGeAlD
Amlexanox—FGF1—female gonad—uterine cancer	0.00813	0.0198	CbGeAlD
Amlexanox—PDE4A—female gonad—uterine cancer	0.00769	0.0187	CbGeAlD
Amlexanox—PDE4B—uterine cervix—uterine cancer	0.00672	0.0163	CbGeAlD
Amlexanox—PDE4B—decidua—uterine cancer	0.00641	0.0156	CbGeAlD
Amlexanox—PDE4B—endometrium—uterine cancer	0.00608	0.0148	CbGeAlD
Amlexanox—PDE4B—mammalian vulva—uterine cancer	0.00588	0.0143	CbGeAlD
Amlexanox—PDE4D—lymph node—uterine cancer	0.00559	0.0136	CbGeAlD
Amlexanox—FGF1—lymph node—uterine cancer	0.00522	0.0127	CbGeAlD
Amlexanox—PDE4B—female reproductive system—uterine cancer	0.00504	0.0122	CbGeAlD
Amlexanox—PDE4A—lymph node—uterine cancer	0.00494	0.012	CbGeAlD
Amlexanox—PDE4B—female gonad—uterine cancer	0.00458	0.0111	CbGeAlD
Amlexanox—PDE4B—vagina—uterine cancer	0.00456	0.0111	CbGeAlD
Amlexanox—PDE4B—lymph node—uterine cancer	0.00295	0.00717	CbGeAlD
Amlexanox—Mouth ulceration—Medroxyprogesterone Acetate—uterine cancer	0.0026	0.0673	CcSEcCtD
Amlexanox—Liver function test abnormal—Progesterone—uterine cancer	0.00213	0.0551	CcSEcCtD
Amlexanox—Mouth ulceration—Dactinomycin—uterine cancer	0.00203	0.0525	CcSEcCtD
Amlexanox—Aphthous stomatitis—Epirubicin—uterine cancer	0.00194	0.0503	CcSEcCtD
Amlexanox—Pain—Carboplatin—uterine cancer	0.00184	0.0477	CcSEcCtD
Amlexanox—Aphthous stomatitis—Doxorubicin—uterine cancer	0.0018	0.0465	CcSEcCtD
Amlexanox—Stomatitis—Medroxyprogesterone Acetate—uterine cancer	0.00157	0.0406	CcSEcCtD
Amlexanox—Liver function test abnormal—Dactinomycin—uterine cancer	0.0015	0.0389	CcSEcCtD
Amlexanox—Mouth ulceration—Etoposide—uterine cancer	0.00147	0.038	CcSEcCtD
Amlexanox—Stomatitis—Dactinomycin—uterine cancer	0.00122	0.0317	CcSEcCtD
Amlexanox—Nervous system disorder—Progesterone—uterine cancer	0.00111	0.0288	CcSEcCtD
Amlexanox—Paraesthesia—Progesterone—uterine cancer	0.00102	0.0263	CcSEcCtD
Amlexanox—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00101	0.0261	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Progesterone—uterine cancer	0.000977	0.0253	CcSEcCtD
Amlexanox—Pain—Progesterone—uterine cancer	0.000968	0.0251	CcSEcCtD
Amlexanox—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000921	0.0239	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000886	0.0229	CcSEcCtD
Amlexanox—Stomatitis—Etoposide—uterine cancer	0.000885	0.0229	CcSEcCtD
Amlexanox—Mouth ulceration—Epirubicin—uterine cancer	0.000823	0.0213	CcSEcCtD
Amlexanox—Mouth ulceration—Doxorubicin—uterine cancer	0.000761	0.0197	CcSEcCtD
Amlexanox—Headache—Progesterone—uterine cancer	0.000709	0.0184	CcSEcCtD
Amlexanox—Pain—Dactinomycin—uterine cancer	0.000684	0.0177	CcSEcCtD
Amlexanox—Nausea—Progesterone—uterine cancer	0.000672	0.0174	CcSEcCtD
Amlexanox—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000643	0.0166	CcSEcCtD
Amlexanox—Liver function test abnormal—Epirubicin—uterine cancer	0.00061	0.0158	CcSEcCtD
Amlexanox—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000609	0.0158	CcSEcCtD
Amlexanox—Liver function test abnormal—Doxorubicin—uterine cancer	0.000564	0.0146	CcSEcCtD
Amlexanox—Paraesthesia—Etoposide—uterine cancer	0.00052	0.0135	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Etoposide—uterine cancer	0.0005	0.013	CcSEcCtD
Amlexanox—Stomatitis—Epirubicin—uterine cancer	0.000496	0.0129	CcSEcCtD
Amlexanox—Pain—Etoposide—uterine cancer	0.000495	0.0128	CcSEcCtD
Amlexanox—Nausea—Dactinomycin—uterine cancer	0.000475	0.0123	CcSEcCtD
Amlexanox—Stomatitis—Doxorubicin—uterine cancer	0.000459	0.0119	CcSEcCtD
Amlexanox—Headache—Etoposide—uterine cancer	0.000363	0.0094	CcSEcCtD
Amlexanox—Nausea—Etoposide—uterine cancer	0.000344	0.00891	CcSEcCtD
Amlexanox—Nervous system disorder—Epirubicin—uterine cancer	0.000318	0.00825	CcSEcCtD
Amlexanox—Nervous system disorder—Doxorubicin—uterine cancer	0.000295	0.00763	CcSEcCtD
Amlexanox—Paraesthesia—Epirubicin—uterine cancer	0.000291	0.00755	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Epirubicin—uterine cancer	0.00028	0.00726	CcSEcCtD
Amlexanox—Pain—Epirubicin—uterine cancer	0.000278	0.00719	CcSEcCtD
Amlexanox—Paraesthesia—Doxorubicin—uterine cancer	0.00027	0.00699	CcSEcCtD
Amlexanox—FGF1—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	0.000259	0.000472	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—ESR1—uterine cancer	0.000259	0.000472	CbGpPWpGaD
Amlexanox—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000259	0.00672	CcSEcCtD
Amlexanox—PDE4D—Signaling Pathways—YWHAE—uterine cancer	0.000259	0.00047	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PGR—uterine cancer	0.000258	0.000469	CbGpPWpGaD
Amlexanox—IL3—Immune System—CTNNB1—uterine cancer	0.000258	0.000468	CbGpPWpGaD
Amlexanox—FGF1—Immune System—SOCS3—uterine cancer	0.000258	0.000468	CbGpPWpGaD
Amlexanox—Pain—Doxorubicin—uterine cancer	0.000257	0.00665	CcSEcCtD
Amlexanox—IL3—Immune System—PTEN—uterine cancer	0.000251	0.000457	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—STK11—uterine cancer	0.000249	0.000452	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—FBXW7—uterine cancer	0.000248	0.000451	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—CCL2—uterine cancer	0.000248	0.00045	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—YWHAE—uterine cancer	0.000246	0.000447	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—NRAS—uterine cancer	0.000245	0.000446	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—AKR1C3—uterine cancer	0.000245	0.000445	CbGpPWpGaD
Amlexanox—FGF1—Signaling by NGF—PIK3CA—uterine cancer	0.000244	0.000444	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—PIK3CA—uterine cancer	0.000244	0.000443	CbGpPWpGaD
Amlexanox—IL3—Immune System—EP300—uterine cancer	0.00024	0.000435	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PGR—uterine cancer	0.000239	0.000434	CbGpPWpGaD
Amlexanox—S100A12—Immune System—ERBB2—uterine cancer	0.000236	0.000429	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—FBXW7—uterine cancer	0.000236	0.000429	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—SOCS3—uterine cancer	0.000233	0.000424	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—ERBB2—uterine cancer	0.000232	0.000421	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—CCL2—uterine cancer	0.000228	0.000415	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—AKR1C3—uterine cancer	0.000228	0.000415	CbGpPWpGaD
Amlexanox—FGF1—Disease—CDKN2B—uterine cancer	0.000228	0.000414	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—YWHAE—uterine cancer	0.000228	0.000414	CbGpPWpGaD
Amlexanox—FGF1—Signaling by NGF—HRAS—uterine cancer	0.000226	0.000411	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—HRAS—uterine cancer	0.000226	0.00041	CbGpPWpGaD
Amlexanox—IL3—Immune System—NRAS—uterine cancer	0.000224	0.000407	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CDKN2B—uterine cancer	0.000223	0.000406	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PGR—uterine cancer	0.000223	0.000405	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—ERBB2—uterine cancer	0.000222	0.000404	CbGpPWpGaD
Amlexanox—S100A12—Immune System—CDKN1B—uterine cancer	0.000219	0.000397	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—FBXW7—uterine cancer	0.000218	0.000397	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—STK11—uterine cancer	0.000217	0.000394	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—IGF1R—uterine cancer	0.000217	0.000394	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—CXCL8—uterine cancer	0.000216	0.000392	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—CCL2—uterine cancer	0.000216	0.000392	CbGpPWpGaD
Amlexanox—FGF1—Immune System—FGFR2—uterine cancer	0.000215	0.000391	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—CDKN1B—uterine cancer	0.000215	0.00039	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—PIK3CA—uterine cancer	0.000214	0.000388	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—YWHAE—uterine cancer	0.000212	0.000386	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—KRAS—uterine cancer	0.000211	0.000384	CbGpPWpGaD
Amlexanox—FGF1—Disease—SMAD3—uterine cancer	0.000208	0.000378	CbGpPWpGaD
Amlexanox—S100A12—Immune System—CTNNB1—uterine cancer	0.000207	0.000375	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—STK11—uterine cancer	0.000206	0.000375	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—CDKN1B—uterine cancer	0.000206	0.000374	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—CCL2—uterine cancer	0.000205	0.000373	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—SMAD3—uterine cancer	0.000204	0.00037	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—FBXW7—uterine cancer	0.000204	0.00037	CbGpPWpGaD
Amlexanox—Headache—Epirubicin—uterine cancer	0.000203	0.00527	CcSEcCtD
Amlexanox—PDE4D—Signaling Pathways—SOCS3—uterine cancer	0.000203	0.000369	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—CTNNB1—uterine cancer	0.000203	0.000368	CbGpPWpGaD
Amlexanox—S100A12—Immune System—PTEN—uterine cancer	0.000201	0.000366	CbGpPWpGaD
Amlexanox—FGF1—Signaling by NGF—AKT1—uterine cancer	0.0002	0.000363	CbGpPWpGaD
Amlexanox—S100A12—Innate Immune System—AKT1—uterine cancer	0.000199	0.000362	CbGpPWpGaD
Amlexanox—FGF1—Disease—FGFR2—uterine cancer	0.000198	0.000361	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—PTEN—uterine cancer	0.000198	0.000359	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—CXCL8—uterine cancer	0.000196	0.000356	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—FGFR2—uterine cancer	0.000194	0.000353	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CDKN2B—uterine cancer	0.000194	0.000353	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—PIK3CA—uterine cancer	0.000194	0.000353	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—SOCS3—uterine cancer	0.000193	0.000351	CbGpPWpGaD
Amlexanox—IL3—Immune System—KRAS—uterine cancer	0.000193	0.000351	CbGpPWpGaD
Amlexanox—Nausea—Epirubicin—uterine cancer	0.000193	0.00499	CcSEcCtD
Amlexanox—S100A12—Immune System—EP300—uterine cancer	0.000192	0.000349	CbGpPWpGaD
Amlexanox—FGF1—Disease—MTHFR—uterine cancer	0.000191	0.000347	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—STK11—uterine cancer	0.000191	0.000347	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—ERBB2—uterine cancer	0.00019	0.000346	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—CCL2—uterine cancer	0.00019	0.000345	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—PTEN—uterine cancer	0.00019	0.000345	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IGF1R—uterine cancer	0.000189	0.000343	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—EP300—uterine cancer	0.000188	0.000342	CbGpPWpGaD
Amlexanox—Headache—Doxorubicin—uterine cancer	0.000188	0.00487	CcSEcCtD
Amlexanox—PDE4D—GPCR downstream signaling—CXCL8—uterine cancer	0.000188	0.000341	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CDKN2B—uterine cancer	0.000185	0.000336	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—CXCL8—uterine cancer	0.000181	0.000328	CbGpPWpGaD
Amlexanox—S100A12—Immune System—NRAS—uterine cancer	0.00018	0.000326	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IGF1R—uterine cancer	0.00018	0.000326	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—HRAS—uterine cancer	0.000179	0.000326	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—CXCL8—uterine cancer	0.000179	0.000325	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—SOCS3—uterine cancer	0.000179	0.000325	CbGpPWpGaD
Amlexanox—Nausea—Doxorubicin—uterine cancer	0.000178	0.00462	CcSEcCtD
Amlexanox—FGF1—Signaling Pathways—STK11—uterine cancer	0.000178	0.000323	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—SMAD3—uterine cancer	0.000177	0.000322	CbGpPWpGaD
Amlexanox—IL3—Immune System—PIK3CA—uterine cancer	0.000177	0.000322	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—CDKN1B—uterine cancer	0.000176	0.000321	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—NRAS—uterine cancer	0.000176	0.00032	CbGpPWpGaD
Amlexanox—IL3—GPCR downstream signaling—AKT1—uterine cancer	0.000174	0.000317	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CDKN2B—uterine cancer	0.000171	0.000311	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—CXCL8—uterine cancer	0.000171	0.00031	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—NRAS—uterine cancer	0.000169	0.000308	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—FGFR2—uterine cancer	0.000169	0.000307	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—SMAD3—uterine cancer	0.000169	0.000307	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—CTNNB1—uterine cancer	0.000167	0.000303	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—SOCS3—uterine cancer	0.000167	0.000303	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—ESR1—uterine cancer	0.000166	0.000302	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IGF1R—uterine cancer	0.000166	0.000302	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—CXCL8—uterine cancer	0.000165	0.000301	CbGpPWpGaD
Amlexanox—IL3—Immune System—HRAS—uterine cancer	0.000164	0.000298	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—PTEN—uterine cancer	0.000162	0.000295	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—CXCL8—uterine cancer	0.000162	0.000295	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—FGFR2—uterine cancer	0.000161	0.000293	CbGpPWpGaD
Amlexanox—FGF1—Immune System—CDH1—uterine cancer	0.00016	0.000291	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CDKN2B—uterine cancer	0.000159	0.00029	CbGpPWpGaD
Amlexanox—IL3—Signaling by GPCR—AKT1—uterine cancer	0.000158	0.000288	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—NRAS—uterine cancer	0.000157	0.000286	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—SMAD3—uterine cancer	0.000156	0.000284	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IGF1R—uterine cancer	0.000155	0.000282	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—EP300—uterine cancer	0.000155	0.000282	CbGpPWpGaD
Amlexanox—S100A12—Immune System—KRAS—uterine cancer	0.000155	0.000281	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—KRAS—uterine cancer	0.000152	0.000276	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—CXCL8—uterine cancer	0.00015	0.000273	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—FGFR2—uterine cancer	0.000149	0.000271	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—VEGFA—uterine cancer	0.000147	0.000267	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CCL2—uterine cancer	0.000146	0.000266	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—KRAS—uterine cancer	0.000146	0.000265	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—SMAD3—uterine cancer	0.000146	0.000265	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—NRAS—uterine cancer	0.000145	0.000263	CbGpPWpGaD
Amlexanox—IL3—Immune System—AKT1—uterine cancer	0.000145	0.000263	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—ESR1—uterine cancer	0.000145	0.000263	CbGpPWpGaD
Amlexanox—S100A12—Immune System—PIK3CA—uterine cancer	0.000142	0.000258	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—PIK3CA—uterine cancer	0.000139	0.000253	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—FGFR2—uterine cancer	0.000139	0.000252	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—ESR1—uterine cancer	0.000138	0.00025	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—PIK3CA—uterine cancer	0.000137	0.000249	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—NRAS—uterine cancer	0.000137	0.000249	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—KRAS—uterine cancer	0.000135	0.000246	CbGpPWpGaD
Amlexanox—FGF1—Immune System—ERBB2—uterine cancer	0.000135	0.000245	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—PIK3CA—uterine cancer	0.000134	0.000243	CbGpPWpGaD
Amlexanox—S100A12—Immune System—HRAS—uterine cancer	0.000131	0.000239	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—NRAS—uterine cancer	0.00013	0.000237	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—HRAS—uterine cancer	0.000129	0.000234	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—ESR1—uterine cancer	0.000127	0.000232	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CCL2—uterine cancer	0.000127	0.000232	CbGpPWpGaD
Amlexanox—FGF1—Immune System—CDKN1B—uterine cancer	0.000125	0.000227	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—KRAS—uterine cancer	0.000125	0.000227	CbGpPWpGaD
Amlexanox—FGF1—Disease—ERBB2—uterine cancer	0.000125	0.000226	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—PIK3CA—uterine cancer	0.000124	0.000226	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—HRAS—uterine cancer	0.000124	0.000225	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—ERBB2—uterine cancer	0.000122	0.000222	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CCL2—uterine cancer	0.000121	0.00022	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—NRAS—uterine cancer	0.00012	0.000219	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—PIK3CA—uterine cancer	0.000119	0.000217	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—ESR1—uterine cancer	0.000119	0.000216	CbGpPWpGaD
Amlexanox—FGF1—Immune System—CTNNB1—uterine cancer	0.000118	0.000215	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—KRAS—uterine cancer	0.000118	0.000214	CbGpPWpGaD
Amlexanox—S100A12—Immune System—AKT1—uterine cancer	0.000116	0.000211	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CXCL8—uterine cancer	0.000116	0.00021	CbGpPWpGaD
Amlexanox—FGF1—Disease—CDKN1B—uterine cancer	0.000115	0.00021	CbGpPWpGaD
Amlexanox—FGF1—Immune System—PTEN—uterine cancer	0.000115	0.000209	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—HRAS—uterine cancer	0.000115	0.000209	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—PIK3CA—uterine cancer	0.000115	0.000208	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—AKT1—uterine cancer	0.000114	0.000207	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—PIK3CA—uterine cancer	0.000113	0.000206	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CDKN1B—uterine cancer	0.000113	0.000205	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CCL2—uterine cancer	0.000112	0.000204	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—KRAS—uterine cancer	0.000112	0.000204	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—AKT1—uterine cancer	0.000112	0.000203	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—TP53—uterine cancer	0.000111	0.000201	CbGpPWpGaD
Amlexanox—FGF1—Immune System—EP300—uterine cancer	0.00011	0.000199	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—AKT1—uterine cancer	0.000109	0.000199	CbGpPWpGaD
Amlexanox—FGF1—Disease—CTNNB1—uterine cancer	0.000109	0.000198	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—PIK3CA—uterine cancer	0.000108	0.000197	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CTNNB1—uterine cancer	0.000107	0.000194	CbGpPWpGaD
Amlexanox—FGF1—Disease—PTEN—uterine cancer	0.000106	0.000193	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—ERBB2—uterine cancer	0.000106	0.000193	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—HRAS—uterine cancer	0.000106	0.000193	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—PIK3CA—uterine cancer	0.000105	0.000191	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CCL2—uterine cancer	0.000105	0.00019	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PTEN—uterine cancer	0.000104	0.000189	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—KRAS—uterine cancer	0.000104	0.000188	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—PIK3CA—uterine cancer	0.000103	0.000187	CbGpPWpGaD
Amlexanox—FGF1—Immune System—NRAS—uterine cancer	0.000103	0.000187	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—AKT1—uterine cancer	0.000102	0.000185	CbGpPWpGaD
Amlexanox—FGF1—Disease—EP300—uterine cancer	0.000101	0.000184	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—ERBB2—uterine cancer	0.000101	0.000184	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CXCL8—uterine cancer	0.000101	0.000183	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—HRAS—uterine cancer	0.0001	0.000182	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—EP300—uterine cancer	9.92e-05	0.00018	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CDKN1B—uterine cancer	9.84e-05	0.000179	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—AKT1—uterine cancer	9.73e-05	0.000177	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CXCL8—uterine cancer	9.59e-05	0.000174	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—PIK3CA—uterine cancer	9.53e-05	0.000173	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—HRAS—uterine cancer	9.53e-05	0.000173	CbGpPWpGaD
Amlexanox—FGF1—Disease—NRAS—uterine cancer	9.48e-05	0.000172	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—VEGFA—uterine cancer	9.4e-05	0.000171	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CDKN1B—uterine cancer	9.36e-05	0.00017	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—AKT1—uterine cancer	9.36e-05	0.00017	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—ERBB2—uterine cancer	9.35e-05	0.00017	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CTNNB1—uterine cancer	9.29e-05	0.000169	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—NRAS—uterine cancer	9.28e-05	0.000169	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—AKT1—uterine cancer	9.26e-05	0.000168	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PTEN—uterine cancer	9.06e-05	0.000165	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CXCL8—uterine cancer	8.87e-05	0.000161	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CTNNB1—uterine cancer	8.85e-05	0.000161	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—AKT1—uterine cancer	8.84e-05	0.000161	CbGpPWpGaD
Amlexanox—FGF1—Immune System—KRAS—uterine cancer	8.83e-05	0.000161	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—HRAS—uterine cancer	8.81e-05	0.00016	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—ERBB2—uterine cancer	8.72e-05	0.000159	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CDKN1B—uterine cancer	8.66e-05	0.000157	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—EP300—uterine cancer	8.64e-05	0.000157	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PTEN—uterine cancer	8.62e-05	0.000157	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—AKT1—uterine cancer	8.57e-05	0.000156	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—AKT1—uterine cancer	8.41e-05	0.000153	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CXCL8—uterine cancer	8.27e-05	0.00015	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—EP300—uterine cancer	8.22e-05	0.000149	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CTNNB1—uterine cancer	8.18e-05	0.000149	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—VEGFA—uterine cancer	8.18e-05	0.000149	CbGpPWpGaD
Amlexanox—FGF1—Disease—KRAS—uterine cancer	8.16e-05	0.000148	CbGpPWpGaD
Amlexanox—FGF1—Immune System—PIK3CA—uterine cancer	8.12e-05	0.000148	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—NRAS—uterine cancer	8.08e-05	0.000147	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CDKN1B—uterine cancer	8.08e-05	0.000147	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—KRAS—uterine cancer	7.99e-05	0.000145	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PTEN—uterine cancer	7.98e-05	0.000145	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—VEGFA—uterine cancer	7.79e-05	0.000142	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—AKT1—uterine cancer	7.78e-05	0.000141	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—NRAS—uterine cancer	7.69e-05	0.00014	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CTNNB1—uterine cancer	7.63e-05	0.000139	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—EP300—uterine cancer	7.61e-05	0.000138	CbGpPWpGaD
Amlexanox—FGF1—Immune System—HRAS—uterine cancer	7.51e-05	0.000136	CbGpPWpGaD
Amlexanox—FGF1—Disease—PIK3CA—uterine cancer	7.49e-05	0.000136	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PTEN—uterine cancer	7.44e-05	0.000135	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PIK3CA—uterine cancer	7.34e-05	0.000133	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—VEGFA—uterine cancer	7.21e-05	0.000131	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—NRAS—uterine cancer	7.12e-05	0.000129	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—TP53—uterine cancer	7.1e-05	0.000129	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—EP300—uterine cancer	7.09e-05	0.000129	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—KRAS—uterine cancer	6.95e-05	0.000126	CbGpPWpGaD
Amlexanox—FGF1—Disease—HRAS—uterine cancer	6.93e-05	0.000126	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—HRAS—uterine cancer	6.79e-05	0.000123	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—VEGFA—uterine cancer	6.72e-05	0.000122	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—NRAS—uterine cancer	6.64e-05	0.000121	CbGpPWpGaD
Amlexanox—FGF1—Immune System—AKT1—uterine cancer	6.63e-05	0.000121	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—KRAS—uterine cancer	6.62e-05	0.00012	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PIK3CA—uterine cancer	6.39e-05	0.000116	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—TP53—uterine cancer	6.18e-05	0.000112	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—KRAS—uterine cancer	6.13e-05	0.000111	CbGpPWpGaD
Amlexanox—FGF1—Disease—AKT1—uterine cancer	6.12e-05	0.000111	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3CA—uterine cancer	6.08e-05	0.000111	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—AKT1—uterine cancer	6e-05	0.000109	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—HRAS—uterine cancer	5.91e-05	0.000107	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—TP53—uterine cancer	5.88e-05	0.000107	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—KRAS—uterine cancer	5.71e-05	0.000104	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CA—uterine cancer	5.63e-05	0.000102	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—HRAS—uterine cancer	5.63e-05	0.000102	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—TP53—uterine cancer	5.44e-05	9.9e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CA—uterine cancer	5.25e-05	9.54e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—AKT1—uterine cancer	5.22e-05	9.49e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—HRAS—uterine cancer	5.21e-05	9.46e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—TP53—uterine cancer	5.08e-05	9.23e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—AKT1—uterine cancer	4.97e-05	9.03e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—HRAS—uterine cancer	4.85e-05	8.83e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—AKT1—uterine cancer	4.6e-05	8.36e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—AKT1—uterine cancer	4.29e-05	7.79e-05	CbGpPWpGaD
